ArQule Announces Presentations on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets & Cancer T...
October 16 2019 - 6:00AM
Business Wire
Two poster presentations on ARQ 751 will
highlight data from the phase 1 trial, as well as preclinical
studies demonstrating the potential of ARQ 751 in combination with
various therapeutic agents
ArQule, Inc. (Nasdaq: ARQL) today announced that it will be
presenting data on the company’s AKT inhibitor, ARQ 751, in two
poster presentations at the 2019 AACR-NCI-EORTC International
Conference on Molecular Targets and Cancer Therapeutics being held
from October 26th to October 30th, 2019 in Boston,
Massachusetts.
Presentations will detail clinical data demonstrating the
correlation between biomarkers and patient response to treatment
with ARQ 751 as well as preclinical in vivo and in vitro findings
supporting the potential of ARQ 751 in combination with a variety
of therapeutic agents.
Details on the presentations are as follows:
Presentation Title: The use of biomarkers and ctDNA in a
phase 1 trial of ARQ 751 Abstract Number: A034
Presenter: Shubham Pant, M.D., MD Anderson Cancer Center
Date: October 27, 2019 Poster Viewing Time: 12:30
p.m.- 4:00 p.m. EDT Location: Hall D, Hynes Convention
Center
Presentation Title: In vitro and in vivo combination of
ARQ 751 with PARP inhibitors, CDK4/6 inhibitors, Fulvestrant and
Paclitaxel Abstract Number: C076 Presenter: Yi Yu,
Ph.D., ArQule Date: October 29, 2019 Poster Viewing
Time: 12:30 p.m.- 4:00 p.m. EDT Location: Hall D, Hynes
Convention Center
Additional details can be found on the conference website. A
copy of presentation materials can be accessed by visiting the
Publications & Presentations section of the ArQule website
after the presentations conclude.
About ARQ 751 ARQ 751 is orally bioavailable, selective
small molecule inhibitor of the AKT serine/threonine kinase. The
AKT pathway when abnormally activated is implicated in multiple
oncogenic processes such as cell proliferation and apoptosis. This
pathway has emerged as a target of potential therapeutic relevance
for compounds that inhibit its activity, which has been linked to a
variety of cancers as well as to select non-oncology
indications.
About ArQule ArQule is a biopharmaceutical company
engaged in the research and development of targeted therapeutics to
treat cancers and rare diseases. ArQule’s mission is to discover,
develop and commercialize novel small molecule drugs in areas of
high unmet need that will dramatically extend and improve the lives
of our patients. Our clinical-stage pipeline consists of four drug
candidates, all of which are in targeted, biomarker-defined patient
populations, making ArQule a leader among companies our size in
precision medicine. ArQule’s pipeline includes: ARQ 531, an orally
bioavailable, potent and reversible dual inhibitor of both wild
type and C481S-mutant BTK, in phase 1/2 for patients with B-cell
malignancies refractory to other therapeutic options; miransertib
(ARQ 092), a potent and selective inhibitor of the AKT
serine/threonine kinase, in a registrational trial with cohorts in
Proteus syndrome and PROS; ARQ 751, a next generation highly potent
and selective AKT inhibitor, in phase 1 for patients with solid
tumors with AKT1 and PI3K mutations; and derazantinib, a
multi-kinase inhibitor designed to preferentially inhibit the
fibroblast growth factor receptor (FGFR) family, in a
registrational trial for iCCA in collaboration with Basilea and
Sinovant. ArQule’s current discovery efforts are focused on the
identification and development of novel kinase inhibitors,
leveraging the Company’s proprietary library of compounds.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191016005130/en/
Corporate: Kathleen Farren Investor Relations &
Executive Assistant to the CFO ir@arqule.com
Media: Cait Williamson, Ph.D. LifeSci Public Relations
(646) 751-4366 cait@lifescipublicrelations.com
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Apr 2024 to May 2024
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From May 2023 to May 2024